temodar

Phase 2Small molecule

DDiakonos Oncology Corporation

temodar is one of 96 small molecule programs targeting Adult Glioblastoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adult GlioblastomaActive, not recruiting

MelanomaActive, not recruiting

Glioblastoma (GBM)Recruiting

Glioblastoma MultiformeActive, not recruiting

Adult GlioblastomaPhase 2

Active, not recruiting

MelanomaPhase 1

Active, not recruiting

Glioblastoma (GBM)Phase 2

Recruiting

Glioblastoma MultiformePhase 2

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 3

11 2

Imjudo

AstraZeneca

Phase 3

2 3

ABI-007

Bristol-Myers Squibb

Phase 3

1 4

Bempegaldesleukin

NNektar Therapeutics

Phase 3

1 5

Single Dose of

Boehringer Ingelheim

Phase 3

1 6

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 7

temodar

DDiakonos Oncology Corporation

Phase 2

4 8

Cancervax Vaccine (CANVAXIN)

CCancerVax Corporation

Phase 3

2 9

Intron a

Merck & Co.

Preclinical

4 10

Opdualag

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 2Recruiting

Glioblastoma (GBM)

NCT06805305

Clinical

Trials by Indication[1]

Melanoma4 trials

Study of Temzolomide and Gleevec in Advanced Melanoma

Terminated·—·Phase 1/2·NCT00667953·32 enrolled

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Unknown status·GGenta Incorporated·Phase 1·NCT00409383·28 enrolled

A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01067066·21 enrolled

Show 1 more trial

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00527761·23 enrolled

Recurrent or Refractory1 trial

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Completed·RRongjie Tao·Phase 2·NCT03660761·25 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors

Completed·UUniversity of California, San Francisco·Phase 2·NCT00187486·66 enrolled

Temozolomide1 trial

Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00508456·18 enrolled

Glioblastoma Multiforme1 trial

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

Terminated·—·Phase 2·NCT01186406·41 enrolled

2 more indications

Neuroendocrine Tumors1 trial

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

Completed·—·Phase 2·NCT00165230·32 enrolled

Glioblastoma (GBM)1 trial

Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination With Standard of Care for Newly Diagnosed Adult Glioblastoma

Recruiting·DDiakonos Oncology Corporation·Phase 2·NCT06805305·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for temodar. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — temodar compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for temodar. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Diakonos Oncology Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDiakonos Oncology Corporation

temodar

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Melanoma4 trials

Recurrent or Refractory1 trial

Safety and Efficacy1 trial

Temozolomide1 trial

Glioblastoma Multiforme1 trial

Neuroendocrine Tumors1 trial

Glioblastoma (GBM)1 trial

References

Drug Info

Quick Facts

Related News